Loading...

PVLA PALVELLA THERAPEUTICS INC Other Situations 8-K Filing

PLVL

PVL

PALVELLA THERAPEUTICS INC

(PVLA)

2026 8-K

Research Update

Stock Market Move

Earnings Results

Board Appointment

Investor Presentation Posted

Earnings Announcement

Stock Offering Details

Preliminary Financials

Investor Conference Call

Positive Study Results

Corporate Presentation

Corporate Presentation Update

Study Results Announcement

Earnings Announcement

Investor Conference Call

Program Expansion

Corporate Presentation Posted

Financial Results Announced

Financial Statements

Earnings Announcement

Investor Presentation

Investor Presentation

Annual Meeting Results

Merger Announcement

Agreement with James Geraghty

Merger Agreement

Termination of Collaboratio...

Compliance Regained

Reverse Stock Split

Financial Condition

Lease Termination

Contract Cancelled

Annual Meeting Approval

Financial Results and Clini...

Discontinuation of Joint Re...

Earnings Reports

Earnings Reports

External Links:

On May 15, 2026, Palvella Therapeutics, Inc. reported new data from their Phase 2 TOIVA trial of QTORIN™ rapamycin, which was presented at the Society for Investigative Dermatology's annual meeting. This event is significant for the company as it highlights important advancements in their clinical research.

AI Assistant

PALVELLA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.